GLP-1 receptor agonists mimic a gut hormone to reduce appetite and slow digestion, used for type 2 diabetes and weight management.
GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone released after eating. They reduce appetite, slow gastric emptying, and improve blood-sugar regulation. FDA-approved examples include semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), a dual GLP-1/GIP agonist. Compounded versions exist but are not FDA-approved.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.